Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. John's wort, feverfew U.S. Pharmacopeia "informational" monographs released.

This article was originally published in The Tan Sheet

Executive Summary

ST. JOHN's WORT USP "INFORMATIONAL" MONOGRAPH for health professionals and consumers recommends against use of the botanical derived from hypericum when taking monoamine oxidase (MAO) inhibitors, selective serotonin reuptake inhibitors or other medications for depression. Released Aug. 10, the U.S. Pharmacopeia monograph notes that while "no drug interactions have been reported" and "it has not been reported specifically in the literature, hypericum has the potential to interact with MAO inhibitors and selective serotonin reuptake inhibitors."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088787

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel